Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Aliment Pharmacol Ther. 2010 Mar;31(6):625-33. doi: 10.1111/j.1365-2036.2009.04218.x. Epub 2009 Dec 10.
The incidence of cholangiocarcinoma is rising. Accurate predictors of survival at diagnosis are not well defined.
To clarify the clinical presentation and prognostic factors of intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma in a contemporary cohort of patients.
Records for consecutive patients at the University of Michigan hospital diagnosed with cholangiocarcinoma between January 2003 and April 2008 were reviewed.
In all, 136 patients had cholangiocarcinoma (79 intra- and 57 extrahepatic cholangiocarcinoma). Median survival was 27.3 months-25.8 months for intrahepatic cholangiocarcinoma and 30.3 months for extrahepatic cholangiocarcinoma. Independent predictors of mortality at presentation on multivariate analysis were elevated bilirubin level (HR 1.04, 95%CI 1.01-1.07), CA 19-9 levels >100 U/mL (HR 1.90, 95%CI 1.17-3.08) and stage of disease (HR 1.51, 95%CI 1.16-1.96). After adjusting for baseline prognostic factors, surgical therapy was associated with improved survival (HR 0.48; 95% CI 0.26-0.88). There were no significant differences regarding clinical presentation, disease stage (P = 0.98), and survival (P = 0.51) between intra- and extrahepatic cholangiocarcinoma.
Survival for cholangiocarcinoma remains poor with no significant difference in outcomes between intra- and extrahepatic cholangiocarcinoma. Stage of disease, bilirubin level and CA 19-9 level are important prognostic factors at presentation. Surgical therapy provides similar efficacy for both tumours when adjusted for other prognostic variables.
胆管癌的发病率正在上升。目前尚不清楚哪些因素能准确预测其诊断时的生存情况。
明确一组当代胆管癌患者的临床表现和预后因素,这些患者既有肝内胆管癌也有肝外胆管癌。
对密歇根大学医院 2003 年 1 月至 2008 年 4 月期间连续诊断为胆管癌的患者的病历进行了回顾性研究。
共纳入 136 例胆管癌患者(79 例肝内胆管癌,57 例肝外胆管癌)。中位生存期为 27.3 个月(肝内胆管癌为 25.8 个月)和 30.3 个月(肝外胆管癌)。多因素分析显示,初诊时胆红素水平升高(HR 1.04,95%CI 1.01-1.07)、CA 19-9 水平>100 U/mL(HR 1.90,95%CI 1.17-3.08)和疾病分期(HR 1.51,95%CI 1.16-1.96)是死亡的独立预测因素。在调整了基线预后因素后,手术治疗与生存改善相关(HR 0.48;95%CI 0.26-0.88)。肝内胆管癌和肝外胆管癌在临床表现、疾病分期(P = 0.98)和生存(P = 0.51)方面均无显著差异。
胆管癌的生存情况仍然较差,肝内胆管癌和肝外胆管癌的预后无显著差异。疾病分期、胆红素水平和 CA 19-9 水平是初诊时的重要预后因素。在调整其他预后变量后,手术治疗对两种肿瘤均具有相似的疗效。